Reporting adverse events is a vital part of post-marketing surveillance of any new medication in determining its safety and efficacy.
Ophthalmologists have a duty of care to report suspected reactions to new medications, as well as outbreaks of conditions such as TASS.
The identification and tracking of cases is a critical means for information to be accurately collected and used in the interest of the vision health of all Canadians.
